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Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive mesenchymal tumor that develops in the abdominal
cavityofyoungmenadults.Patientstypicallypresentwithsymptomsofabdominalsarcomatosis.Diagnosisisbasedonhistological
analysis of biopsies which typically show small round blue cells in nests separated by an abundant desmoplastic stroma. DSRCT is
associated with a unique chromosomal translocation t(11:22) (p 13; q 12) that involves the EWSR1 and WT1genes. The prognosis
is particularly poor; median survival ranges from 17 to 25 months, largely due to the presentation of the majority of patients
with metastatic disease. Management of DSRCT remains challenging and current schemes lack a signiﬁcant cure rate despite
the use of aggressive treatments such as polychemotherapy, debulking surgery and whole abdominal radiation. Several methods
are being evaluated to improve survival: addition of chemotherapy and targeted therapies to standard neoadjuvant protocol,
completionofsurgicalresectionwithHIPEC,postoperativeIMRT,treatmentofhepaticmetastaseswith[90Y]Yttriummicrosphere
liver embolization.
1.Introduction
Desmoplastic small round cell tumor (DSRCT) is a rare
and highly aggressive mesenchymal tumor that was ﬁrst
described as a separate identity in 1989 by Gerald and Rosai
[1]; since that time, fewer than 200 cases have been reported
in the literature.
DSRCT mainly develops in adolescent and young adults
with a strong male predominance; the mean age at diagnosis
is approximately 22 years and ranges from 6 to 49 years,
the male to female ratio is 4:1 [2]. The tumor typically
develops in the abdominal cavity, invading the omentum
with multiple peritoneal implants involving the diaphragm,
splenic hilum, mesentery of small and large bowel, and the
pelvic peritoneum. Organ involvement is inconstant and
secondary,withliverandlungastwocommonsitesformeta-
static disease beyond the peritoneum. Involvement of extra-
peritoneal organs, such as the testes, ovaries, and pleura has
been described in literature. Distant metastasis may occur
later [3].
As for of others intraabdominal tumors, patients may
be asymptomatic for long periods of time and diagnosis
is made when tumor burden is large. Clinically, patients
presentsymptomsofabdominalsarcomatosissuchasascites,
abdominal pain and/or distension, constipation or bowel
obstruction, vomiting, and weight loss.
Abdominal imaging by ultrasound, computed tomog-
raphy scan or magnetic resonance imaging reveals mul-
tiple peritoneal masses (from millimeter sized nodules to
conﬂuent sheets and dozens to hundreds of nodules up
to 20cm or greater). For complete staging, the search for
visceralmetastasis(hepatic and/or pulmonary) withCT scan
is typically used.2 Sarcoma
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2.DiagnosisandStaging
Diagnosis is based on histological analysis of biopsies
which typically shows small round blue cells in nests
separated by an abundant desmoplastic stroma. By light
microscopy,tumorcellsshowimmunohistochemicalreactiv-
ityforepithelial(keratin,epithelialmembraneantigen),neu-
ral (neuron-speciﬁc enolase), and muscle (desmin) markers
[4]. DSRCT is associated with a unique chromosomal
translocation t(11:22) (p 13; q 12) that involves the EWSR1
and WT1 genes [5–7]. The translocation results in a fusion
of the 2 genes with expression of an oncogenic chimeric
EWSR1-WT1 protein that acts as a transcriptional regulator
that alters gene expression and ultimately permits tumor
growth.
DSRCT is a member of the large family of small round
cell tumors of childhood, together with PNET (Ewing sar-
coma), alveolar and embryonal rhabdomyosarcoma, poorly
diﬀerentiated synovial sarcoma and rhabdoid tumors.
Disease staging and stage classiﬁcations are essential to
patient management and allow the comparison of diﬀer-
ent therapeutic strategies. However, there is currently no
validated staging system for DSRCT and using the UICC
staging for sarcoma would lead to the classiﬁcation of nearly
all patients as having stage IV disease. Despite aggressive
multimodal treatment, median survival ranges from 17 to 25
months, with fewer than 20% of patients achieving 5-year
survival.
Several staging systems have been proposed to classify
peritoneal carcinomatosis. Such a classiﬁcation is essential
to categorise patients and to propose and compare diﬀerent
therapeutic strategies. The staging system currently used is
the Peritoneal Cancer Index (PCI), describing 4 stages [8].
Figure 1 presents the PCI.
Recently, investigators at the MD Anderson Cancer
Center suggested a new staging system based on the PCI
Table 1
Stage PCI Liver metastasis Extraabdominal metastasis
I <12 No No
II >12 No No
III Any PCI Yes No
I V A n yP C I Y e so rn o Y e s
and the presence of liver metastases and extra-abdominal
metastases [9]. Table 1 presents this staging system.
Although promising this staging system needs to be
validated in larger cohorts and in other institutions.
3.MolecularBiology
The unique translocation found in DSRCT involves EWSR1
and WT1 genes. EWSR1 encodes the EWS protein which
is a member of the FET family of RNA-binding proteins,
while WT1 encodes a zinc-ﬁnger transcription factor. The
t(11; 22) found in DSRCT leads to the fusion of the 5 to
9ﬁ r s te x o n so fEWSR1 and the 3 last exons of WT1 [10].
The fusion product is a 59kDa protein containing the N-
terminal portion of EWS, which has strong transactivational
properties, and the last three zinc-ﬁnger domains of WT1,
which acts as an AND-binding domain. The EWSR1-WT1
chimeric protein therefore acts as an oncogenic transcription
factor as evidenced by its ability to transform NIH3T3 cells
[11]. Several transcriptional targets of the EWSR1-WT1
chimerahavebeenidentiﬁedsuchasPlateletDerivedGrowth
Factor A (PDGFA), IL2 receptor β, Myeloid Leukemia Factor
1 (MLF1) or Insulin-like Growth Factor 1 receptor (IGF1-
R); however, their precise contribution to transformation
and their potential as a therapeutic target remain poorly
understood.Sarcoma 3
Table 2
Author Drug Number of cases Beneﬁt
Thijs et al., 2010 [12] Temsirolimus 1 PFS 40 weeks
Lopez-Gonzales, 2011 [13] Cisplatin-Campto trabectedin 1 PDPFS 8 months
Chao, 2010 Imatinib mesylate 2 PFS 0.2 and 1.1 months
Mrabti et al., 2011 [14] Anthracyclin 1 —
Outc’s observatory ASCO 2010 #10097 Sunitinib 2 PFS 2 and 6 months
Outc’s observatory ASCO 2010 #10097 Sorafenib 2 PFS 3 months: stop at 3 months for toxicity
4. Management of Patients with DSRCT
Therapeutic management of DSRCT remains challenging
with low eﬃcacy despite the combination of aggressive
treatmentssuchaspolychemotherapy,debulkingsurgeryand
whole abdominal radiation.
Aggressive surgical debulking is the mainstay of the ther-
apeutic strategy. Debulking surgery is deﬁned as deﬁnitive
removal of at least 90% of the tumor burden. Two retro-
spective studies of prognostic factors in 32 and 66 patients
with DSRCT respectively, identiﬁed gross tumor resection as
a highly signiﬁcant predictor of prolonged overall survival
[15, 16]. Lal et al. reported a 3-years survival of 58% in
patients treated with debulking compared to no survivors
beyond 3 years in the nonresection cohort (P<0.00001).
DSRCT is known to be at least somewhat chemosensitive
[17] and radiosensitive tumor. The main series evaluating
the eﬃcacy of chemotherapy was reported in 1996 by
Kushner et al. [18]. Twelve patients were treated with the P6
protocol: 7 courses of chemotherapy with cyclophosphamide
(4200mg/m2), doxorubicin (75mg/m2) and vincristine
(HD-CAV) alternating with ifosfamide (9 to 12mg/m2)a n d
etoposide (500 to 1000mg/m2). All tumors responded to
HD-CAV, but there were no pathological complete response.
Two patients died after chemotherapy (1 Budd-Chiari syn-
drome and 1 infectious complication). Following response
to this induction regimen, tumor resection was attempted;
local radiotherapy and myeloablative regimen comprising
thiotepa (900mg/m2) plus carboplatin (1500mg/m2)w i t h
stem cell rescue were administered to 5 and 4 patients,
respectively. The median survival time was 19 months for
all patients and 22 months for the 7 achieving complete
response tochemotherapy. An ongoingtrial ofNCI evaluates
the addition of irinotecan, temozolomide, and bevacizumab
to P6 protocol. It is also not clear if such high doses of
chemotherapy are any more useful than standard doses of
chemotherapy employed in Ewing sarcoma and similar small
roundcelltumors.Giventhepoorsurvivaldespitethesehigh
chemotherapy doses, in the adult population we generally
employ lower doses than those described in the Kushner
paper.
When such aggressive strategies are not possible, several
case reports describing modest activity with anthracyclin-
based regimen, trabectedin, or temsirolimus are found in the
literature [12–14].
Table 2 presents the eﬃcacy of treatments in relapse
setting.
Several authors have advocated the use of hyperthermic
intraperitoneal chemotherapy (HIPEC) following optimal
debulking in patients with DSRCT. Most patients with
DSRCT present with dozens to hundreds of nodules on
peritoneum and surgical excision ensuring no microscopic
residue is almost impossible to achieve. Eﬃcacy of HIPEC
has already been established in peritoneal carcinomatosis
secondary to ovarian carcinoma, prolonging survival at the
cost of an increased toxicity. In DSRCT, HIPEC has been
given as heated cisplatin at a dose of 100 to 150mg/m2.
After some case reports, Hayes-Jordan et al. published in
2010 the only one series of DSRCT treated with HIPEC
[9, 19]. Retrospective review was performed for 24 patients
with DSRCT. Three subgroups were deﬁned according to
theirtreatmentandcompared:9patients receivednosurgery
and were treated with chemo and/or radiotherapy (group
1), 7 patients received debulking surgery (group 2) and 8
patients received cytoreductive surgery and HIPEC (group
3). All patients received neo-adjuvant chemotherapy and
some of them abdominal radiation, stem cell transplant
and/or immunotherapy. Postoperative chemotherapy with
12 cycles of temozolomide and irinotecan was administered
in Aguilera report [19]. The 3-year survival in patients
who underwent cytoreductive surgery with HIPEC was 71%,
not statistically diﬀerent when compared with 62% 3 years
survival of patients who were treated with surgery alone.
The authors explain the lack of statistical signiﬁcance with
the limited size of the sample. Conversely, surgery with or
without HIPEC clearly improves survival when compared
to patients treated with medical therapy alone (26% 3-years
survival). Two more important messages are brought by
the article: ﬁrst, HIPEC seems safer technically in children
(rather than in adults); secondly, presence of liver metastasis
is not an independent pejorative prognostic factor, but
disease outside abdomen is. A prospective phase II study
is ongoing, to better deﬁne the beneﬁt of HIPEC added to
cytoreductive surgery in DSRCT. Overall, data supporting
the use of HIPEC in patients with DSRCT is limited and
this technique is not recommended for the management of
patients with DSRCT outside clinical trials.
Whole abdominopelvic (WAP) radiotherapy has also
been proposed as an adjunct to (complete) surgery with
the aim to improve local control. This is based on a
report from investigators at the Memorial Sloan Kettering
Cancer Center investigating WAP in patients with DSRCT.
In this study, patients received induction chemotherapy with
the P6 regimen for 7 cycles. Following chemotherapy and4 Sarcoma
maximal surgical debulking, 21 patients received external
beam radiotherapy to the whole abdomen and pelvis to a
dose of 30Gy plus a radiation boost to remaining tumor sites
for patients with gross residual disease. WAP was associated
with signiﬁcant gastrointestinal and haematological toxicity
(requiring red blood cell transfusion and GCSF support
in some patients). Long-term toxicity consisted of small
bowel obstruction (7/21 patients) and ureteral stenosis (2/21
patients). Furthermore, most of the patients relapsed (16
of 21, 76%) and eventually died of their disease while one
patient died of acute leukemia while in complete response.
All of the 16 relapses were seen in the radiation ﬁeld. Overall
only 2 patients (10%) were alive and disease-free at last
follow-up,datathatappearnodiﬀerentthanothercaseseries
in the literature.
More recently, Pinnix et al. reported a series of 8 patients
treated with whole abdominopelvic Intensity-Modulated
Radiation Therapy (IMRT) after neoadjuvant chemotherapy
and debulking surgery (and HIPEC for 7 patients) [20].
They conclude that postoperative IMRT is feasible and well
tolerated after aggressive surgery with no grade 4 digestive
symptoms, red-cell transfusions in only 2 patients and grade
4 cytopenia in only 1 patient. No other cytopenia was
noted. Among these 8 patients, only 1 did not relapse
after 20 months follow-up. Based on these reports, WAP
radiotherapy (WAP-RT) appears feasible in patients with
DSRCT,butisassociatedwithsigniﬁcanttoxicityandlimited
eﬃcacy. Again, with no survival signal in the studies to date,
it is diﬃcult to recommend this modality outside of a clinical
trial.
Recently, Subbiah et al. reported the case of a young
patient with hepatic metastasis of DSRCT resistant to
chemotherapy successfully treated with [90Y]Yttrium micro-
spheres given by hepatic artery embolization with evident
metabolic response on PET-CT [21]. Given the ﬁnding of
peritoneal disease in most patients, it seems therapy by
hepatic artery infusion will have a very limited place in
treatment of DSRCT.
5. Conclusion
Despite its rarity, several new procedures have been tested
in DSRCT in this particularly severe tumor aﬀecting chil-
dren, without evidence of clinical utility. The combination
of Ewing-sarcoma-based polychemotherapy and debulking
surgery represent the standard of care as of early 2012.
Not surprisingly, those patients having successful surgical
debulking and responsive disease to chemotherapy appear
to have the best outcome compared to groups of patients
who do not achieve both favorable outcomes. The impact of
new techniques such as HIPEC or IMRT needs to be clearly
deﬁned, ideally in the context of prospective randomized
clinicaltrialssincetheretrospectivedatatodategivenosense
of a positive survival signal. Whole genome sequencing of
DSRCT is ongoing to identify mutations, single nucleotide
polymorphisms or copy number changes associated with
these tumors to explore pathogenesis and open medical
therapeutic possibilities.
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